MTP - マイダテック・ファ―マ （Midatech Pharma PLC）

Midatech Pharma (BDRX) stock is rocketing higher on Tuesday after the pharmaceutical company announced a new research program.

Midatech announced on 9 February a private placement to certain US institutional investors to raise US$6m (£5m) in gross proceeds. The issue will comprise 10.3m ADS units (or ADS-equivalent pre-fun…

Midatech Pharma (MTP) received a notice from Nasdaq for not being in compliance with the $1 minimum bid price requirement rule for continued listing on the exchnage.The…

NEW HAVEN, Conn., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI) (the “ Company ” or “ Bioasis ”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB 3 ™ platform for delivering therapeutics across the blood-brain barrier (“ BBB ”) and the treatment of central nervous system (“ CNS ”) disorders in areas of high unmet medical need, today announced that it has terminated the arrangement agreement (the “ Arrangement Agreement ”) dated December 13, 2022, as amended December 18, 2022, between Bioasis and Midatech Pharma plc (“ Midatech ”). The Arrangement Agreement provided for Midatech’s acquisition of all of Bioasis’ issued and outstanding shares in exchange for ordinary shares of Midatech by way of a statutory plan of arrangement under the laws of British Columbia (the “ Arrangement ”).

By Anthony O. Goriainoff Shares in Midatech Pharma PLC rose Monday after the company said it had agreed to revise the terms of a private placement, and that…

Midatech Pharma (BDRX) stock is rocketing higher on Tuesday after the pharmaceutical company announced a new research program.

Midatech announced on 9 February a private placement to certain US institutional investors to raise US$6m (£5m) in gross proceeds. The issue will comprise 10.3m ADS units (or ADS-equivalent pre-fun…

Midatech Pharma (MTP) received a notice from Nasdaq for not being in compliance with the $1 minimum bid price requirement rule for continued listing on the exchnage.The…

NEW HAVEN, Conn., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI) (the “ Company ” or “ Bioasis ”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB 3 ™ platform for delivering therapeutics across the blood-brain barrier (“ BBB ”) and the treatment of central nervous system (“ CNS ”) disorders in areas of high unmet medical need, today announced that it has terminated the arrangement agreement (the “ Arrangement Agreement ”) dated December 13, 2022, as amended December 18, 2022, between Bioasis and Midatech Pharma plc (“ Midatech ”). The Arrangement Agreement provided for Midatech’s acquisition of all of Bioasis’ issued and outstanding shares in exchange for ordinary shares of Midatech by way of a statutory plan of arrangement under the laws of British Columbia (the “ Arrangement ”).

By Anthony O. Goriainoff Shares in Midatech Pharma PLC rose Monday after the company said it had agreed to revise the terms of a private placement, and that…

Midatech Pharma press release (MTP): FY Cash and deposits at 31 December 2021 of £10.06M (2020: £7.55M).Net loss from continuing operations of £5.46M (2020: £22.19M loss).Net cash…

ABINGDON, OXFORDSHIRE / ACCESSWIRE / April 26, 2022 / Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces its audited preliminary results for the …

Midatech Pharma (MTP) received a letter from the Listings Qualifications Department of the Nasdaq that it is not in compliance with the minimum bid price.The notification does not lead…

ABINGDON, OXFORDSHIRE / ACCESSWIRE / April 14, 2022 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it received written …

Johnson & Johnson (JNJ) Janssen unit and U.K.-based Midatech Pharma are extending a research collaboration to include a second molecule.